Antineoplastic and Immunosuppressive Agents Part I

  • Alan C. Sartorelli
  • David G. Johns

Table of contents

  1. Front Matter
    Pages I-XXIV
  2. General Considerations: Antineoplastic Agents

    1. C. Gordon Zubrod
      Pages 1-11
    2. Abraham Goldin, Stephen Carter, Nathan Mantel
      Pages 12-32
    3. W. C. J. Ross
      Pages 33-51
    4. J. A. R. Mead
      Pages 52-75
    5. John A. Montgomery
      Pages 76-111
    6. Leroy B. Townsend, C. C. Cheng
      Pages 112-141
    7. L. F. Lamerton
      Pages 142-155
    8. Bayard Clarkson
      Pages 156-193
    9. Elton Stubblefield, Sandra Murphree
      Pages 194-204
    10. H. Madoc-Jones, F. Mauro
      Pages 205-219
    11. Daniel S. Zaharko, Robert L. Dedrick
      Pages 220-228
    12. M. T. Hakala
      Pages 240-269
    13. Alan L. Cowles, Joseph D. Fenstermacher
      Pages 319-329
    14. J. Frank Henderson
      Pages 341-351
    15. E. W. Brockman
      Pages 352-410

About this book

Introduction

Over the past two decades a number of attempts have been made, with varying degrees of success, to collect in a single treatise available information on the basic and applied pharmacology and biochemical mechanism of action of antineoplastic and immunosuppressive agents. The logarithmic growth of knowledge in this field has made it progressively more difficult to do justice to all aspects of this topic, and it is possible that the present handbook, more than four years in preparation, may be the last attempt to survey in a. single volume the entire field of drugs em­ ployed in cancer chemotherapy and immunosuppression. Even in the present instance, it has proved necessary for practical reasons to publish the material in two parts, although the plan of the work constitutes, at least in the editors' view, a single integrated treatment of this research area. A number of factors have contributed to the continuous expansion of research in the areas of cancer chemotherapy and immunosuppression. Active compounds have been emerging at ever-increasing rates from experimental tumor screening systems maintained by a variety of private and governmental laboratories through­ out the world. At the molecular level, knowledge of the modes of action of estab­ lished agents has continued to expand, and has permitted rational drug design to playa significantly greater role in a process which, in its early years, depended almost completely upon empirical and fortuitous observations.

Keywords

Immunsuppression Krebs Strahlentherapie Zytostatikum agents therapy

Editors and affiliations

  • Alan C. Sartorelli
    • 1
  • David G. Johns
    • 2
  1. 1.Department of PharmacologyYale University School of MedicineNew HavenUSA
  2. 2.Laboratory of Chemical Pharmacology, National Cancer InstituteNational Istitutes of HealthBethesdaUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-642-65678-1
  • Copyright Information Springer-Verlag Berlin Heidelberg 1974
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-65680-4
  • Online ISBN 978-3-642-65678-1
  • Series Print ISSN 0171-2004
  • Series Online ISSN 1865-0325
  • About this book
Industry Sectors
Biotechnology
Pharma